BioMarin Pharmaceutical Inc. (BMRN) 은(는) 상장 기업입니다 헬스케어 섹터의 바이오 산업에서 운영. 본사 소재지는 San Rafael, CA, 미국. 현재 CEO는 Alexander Hardy.
BMRN 을(를) 보유 IPO 날짜 1999-07-26, 3,040 명의 정규직 직원, 에 상장 NASDAQ Global Select, 시가총액 $10.67B.
BioMarin Pharmaceutical Inc. is a biopharmaceutical company that develops and commercializes therapies for rare and life-threatening genetic and metabolic diseases. The company's approved commercial products include Vimizim and Naglazyme for mucopolysaccharidosis disorders, Kuvan and Palynziq for phenylketonuria, Brineura for Batten disease, Voxzogo for achondroplasia, and Aldurazyme for lysosomal storage disease. BioMarin's pipeline includes late-stage gene therapy candidates such as valoctocogene roxaparvovec for hemophilia A and BMN 307 for phenylketonuria, along with BMN 255 in development for primary hyperoxaluria. The company distributes its products globally through specialty pharmacies, hospitals, and pharmaceutical wholesalers across the United States, Europe, Latin America, and international markets, while maintaining strategic partnerships with leading biotechnology firms.
